UNBSF
Uni-Bio Science Group Limited, an investment holding company, researches and develops, manufactures, and sells biological and chemical pharmaceutical products to treat human diseases in the People's Republic of China. It operates through Chemical Pharmaceutical Products, Biological Pharmaceutical Products, and Pipeline Products segments. The company provides BOGUTAI, a disposable injection pen fo… Read more
UNBSF (UNBSF) - Net Assets
Latest net assets as of June 2025: $382.85 Million USD
Based on the latest financial reports, UNBSF (UNBSF) has net assets worth $382.85 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($556.05 Million) and total liabilities ($173.20 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $382.85 Million |
| % of Total Assets | 68.85% |
| Annual Growth Rate | 14.51% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 15.52 |
UNBSF - Net Assets Trend (2020–2024)
This chart illustrates how UNBSF's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for UNBSF (2020–2024)
The table below shows the annual net assets of UNBSF from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $325.64 Million | +26.62% |
| 2023-12-31 | $257.17 Million | +32.06% |
| 2022-12-31 | $194.75 Million | +11.73% |
| 2021-12-31 | $174.31 Million | -7.97% |
| 2020-12-31 | $189.41 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to UNBSF's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 17375900000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $2.16 Billion | 663.90% |
| Total Equity | $325.64 Million | 100.00% |
UNBSF Competitors by Market Cap
The table below lists competitors of UNBSF ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sun Summit Minerals Corp
OTCQB:SMREF
|
$12.46 Million |
|
Garuda Indonesia Persero Tbk
JK:GIAA
|
$12.47 Million |
|
Mikobeaute International Co., Ltd.
TWO:6574
|
$12.47 Million |
|
MIG Holdings S.A.
F:M3K0
|
$12.47 Million |
|
Mongolia Growth Group Ltd.
PINK:MNGGF
|
$12.45 Million |
|
Landis Taipei Hotel Co Ltd
TWO:5703
|
$12.45 Million |
|
ALBIS Leasing AG
XETRA:ALG
|
$12.44 Million |
|
Bergen Carbon Solutions A/S
OL:BCS
|
$12.44 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in UNBSF's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 257,174,000 to 325,645,000, a change of 68,471,000 (26.6%).
- Net income of 82,774,000 contributed positively to equity growth.
- Share repurchases of 24,833,000 reduced equity.
- Other factors increased equity by 10,530,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $82.77 Million | +25.42% |
| Share Repurchases | $24.83 Million | -7.63% |
| Other Changes | $10.53 Million | +3.23% |
| Total Change | $- | 26.62% |
Book Value vs Market Value Analysis
This analysis compares UNBSF's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.07x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $0.03 | $0.00 | x |
| 2021-12-31 | $0.03 | $0.00 | x |
| 2022-12-31 | $0.03 | $0.00 | x |
| 2023-12-31 | $0.04 | $0.00 | x |
| 2024-12-31 | $0.05 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently UNBSF utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 25.42%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.97%
- • Asset Turnover: 1.07x
- • Equity Multiplier: 1.59x
- Recent ROE (25.42%) is above the historical average (4.77%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -37.65% | -34.16% | 0.83x | 1.33x | $-90.26 Million |
| 2021 | -11.24% | -5.54% | 1.32x | 1.54x | $-37.02 Million |
| 2022 | 19.78% | 8.75% | 1.51x | 1.50x | $19.04 Million |
| 2023 | 27.56% | 14.62% | 1.18x | 1.59x | $45.16 Million |
| 2024 | 25.42% | 14.97% | 1.07x | 1.59x | $50.21 Million |
Industry Comparison
This section compares UNBSF's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| UNBSF (UNBSF) | $382.85 Million | -37.65% | 0.45x | $12.45 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |